Acadia Pharmaceuticals obtained FDA approval for the drug Daybue, the first drug for Rett syndrome, after acquiring rights to it and investing a significant amount of money. They were awarded a priority review voucher with the approval, which allows for expedited review of future drugs. Acadia sold this voucher for $150 million, with $50 million going to Neuren Pharmaceuticals as part of their licensing agreement. The FDA is phasing out the priority review voucher program, making them highly sought after. Acadia has also secured global rights to NNZ-2591, expanding their product portfolio. Sales of Daybue are expected to reach up to $350 million in 2024, with proceeds from the voucher sale supporting various company operations.
Source link
Acadia Pharma Sells Voucher for Speedier FDA Drug Review for $150M
